FONAR To Be Taken Private In CEO-Led Acquisition For $19 Per Share

FONAR agreed to be acquired and taken private by a buyer group led by CEO Timothy Damadian, with common and Class B shareholders to receive $19.00 per share, Class C $6.34, and Class A non-voting preferred $10.50 — a 31.5% premium to the last close. The transaction, unanimously recommended by a special committee and approved by the disinterested board, carries committed financing including a $35M debt facility from OceanFirst Bank, about $10M subordinated debt and roughly $45M in equity contributions, is not subject to financing contingencies, and is expected to close in fiscal Q3 2026 with subsequent Nasdaq delisting. FONR traded between $12.00 and $17.62 over the past year, closed at $14.66 pre-announcement and jumped to $18.25 in overnight trading, hitting a new 52-week high.

Analysis

Market structure: Insider-led take-private benefits the acquisition group (Timothy Damadian and co.) and existing common holders who tender at $19; public float holders lose ongoing upside and liquidity as shares will delist. The 31.5% headline premium compresses optionality; expect short-term buying interest to push price toward $19, reducing float and making small-cap med-device stocks relatively less liquid and more takeover-prone. Cross-asset: minimal macro impact — $35m committed bank facility (OceanFirst) is immaterial to credit markets, options liquidity will evaporate on delisting, and FX/commodities unaffected.

Risk assessment: Main tail risks are failed shareholder approval, class-action suits (notably from Class C holders receiving $6.34), or proxy-contest delays; these could drop the stock >30% from current levels. Time horizon matters: immediate (days) — price re-rates toward $19; short-term (weeks–months) — proxy and competing bid risk; long-term (quarters) — delisting and operational execution under private ownership. Hidden dependencies include unequal class consideration that raises litigation probability and contingent liabilities revealed in S-4/DEFA14A filings.

Trade implications: Pure arbitrage has low gross return: $19 vs $18.25 implies ~4.2% upside; acceptable only if close <=12 months and legal risk low. If spread ≥2% with clear shareholder support, a small cash-heavy arbitrage sized 2–4% NAV is warranted, with stop at $17. For broader rotation, trim small-cap med-device exposure by 1–3% and redeploy into liquid large-cap healthcare-equipment names (GE, ticker GE; Medtronic, MDT) to capture sector consolidation without delisting risk.

Contrarian angles: Consensus underestimates litigation/class conflict risk from heavily discounted Class C consideration — this is a binary that could blow out the spread. Historical parallels (insider-led buyouts with unequal class treatment) show 10–40% downside in contested cases; thus current overnight pop to $18.25 may be overdone. Key monitoring: DEFA14A/DEFM14A proxy disclosures and any 13D/13E-3 filings within 30–90 days — these will recalibrate arbitrage sizing quickly.

Key Decisions for Investors

• Establish a disciplined event-arb long in FONR sized 2–4% of NAV only if market price ≤ $18.30 (spread ≥ ~3%); target takeout at $19 within 12 months, set hard stop-loss at $17 and trim if DEFA14A shows material contingent liabilities.
• If FONR weakness pushes price < $16.50 (implying ≥13% downside to deal), consider opportunistic add to 5% NAV as a distressed special situation, but hedge legal risk by light short exposure to small-cap medical-device index or peers.
• Reduce small-cap medical-device exposure by 1–3% of portfolio and redeploy into large-cap healthcare-equipment names: overweight GE (GE) and Medtronic (MDT) by 1–2% each to capture consolidation benefits and preserve liquidity.
• Monitor dossier triggers: require receipt of DEFA14A/proxy and Schedule 13E-3 within 30–90 days; if evidence of class-action filings or a competing bidder appears, unwind arb positions if spread widens > $2 or if proxy vote outcome is uncertain.